Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Erectile Dysfunction Pipeline Drugs Market Overview

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use, and medications, including antidepressants, antihistamines, and medications to treat high blood pressure, pain, or prostate cancer.

The Erectile Dysfunction drugs in development market research report provide comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

Key Targets in the Erectile Dysfunction Pipeline Products Market

The key targets in the Erectile Dysfunction pipeline products market are Phosphodiesterase 5, Sodium Dependent Dopamine Transporter, D1A Dopamine Receptor, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, Adenosine Receptor A3, Angiopoietin 1 Receptor, Beta 3 Adrenergic Receptor, and others.

Erectile Dysfunction Pipeline Products Analysis Market by Targets

Erectile Dysfunction Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Erectile Dysfunction Pipeline Products Market

The key mechanisms of action in the Erectile Dysfunction pipeline products market are Phosphodiesterase 5 Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D1A Dopamine Receptor Agonist, D2 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, Adenosine Receptor A3 Agonist, Angiopoietin 1 Receptor Agonist, Beta 3 Adrenergic Receptor Agonist, and others.

Erectile Dysfunction Pipeline Products Market Analysis by Mechanism of Actions

Erectile Dysfunction Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Erectile Dysfunction Pipeline Products Market

The key routes of administration in the Erectile Dysfunction pipeline products market are oral, topical, sublingual, intracavernous, intramuscular, nasal, parenteral, buccal, inhalational, intracardiac, and others.

Erectile Dysfunction Pipeline Products Market Analysis by Routes of Administration

Erectile Dysfunction Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Erectile Dysfunction Pipeline Products Market

The key molecule types in the Erectile Dysfunction pipeline products market are small molecule, cell therapy, biologic, fusion protein, recombinant protein, antisense RNAi oligonucleotide, gene therapy, and RNAi gene therapy.

Erectile Dysfunction Pipeline Products Market Analysis by Molecule Type

Erectile Dysfunction Pipeline Products Market Analysis by Molecule TypeFor more molecule type insights, download a free report sample

Major Companies in the Erectile Dysfunction Pipeline Products Market

Some of the major companies in the Erectile Dysfunction pipeline products market are Chengdu Dikang Pharmaceuticals Co Ltd, Initiator Pharma AS, NAL Pharmaceuticals Ltd, AnyGen Co Ltd, Aprogen Inc, Aquestive Therapeutics Inc, Arovella Therapeutics Ltd, Astellas Pharma Inc, Autotelic Bio Inct, and Benuvia Therapeutics Inc.

Erectile Dysfunction Pipeline Products Market Analysis by Companies

Erectile Dysfunction Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Phosphodiesterase 5, Sodium Dependent Dopamine Transporter, D1A Dopamine Receptor, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, Adenosine Receptor A3, Angiopoietin 1 Receptor, Beta 3 Adrenergic Receptor, and others
Key mechanism of action Phosphodiesterase 5 Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D1A Dopamine Receptor Agonist, D2 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, Adenosine Receptor A3 Agonist, Angiopoietin 1 Receptor Agonist, Beta 3 Adrenergic Receptor Agonist, and others
Key routes of administration Oral, Topical, Sublingual, Intracavernous, Intramuscular, Nasal, Parenteral, Buccal, Inhalational, Intracardiac, and Others
Key molecule type Small Molecule, Cell Therapy, Biologic, Fusion Protein, Recombinant Protein, Antisense RNAi Oligonucleotide, Gene Therapy, and RNAi Gene Therapy
Major companies Chengdu Dikang Pharmaceuticals Co Ltd, Initiator Pharma AS, NAL Pharmaceuticals Ltd, AnyGen Co Ltd, Aprogen Inc, Aquestive Therapeutics Inc, Arovella Therapeutics Ltd, Astellas Pharma Inc, Autotelic Bio Inct, and Benuvia Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AnyGen Co Ltd
Aprogen Inc
Aquestive Therapeutics Inc
Arovella Therapeutics Ltd
Astellas Pharma Inc
Autotelic Bio Inc
Benuvia Therapeutics Inc
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Chengdu Dikang Pharmaceuticals Co Ltd
Cure Pharmaceutical Holding Corp
Dicot AB
Evincis Bio Inc
Exopharm Ltd
Fabre-Kramer Pharmaceuticals Inc
Farmalider SA
Guangzhou Four-Leaf Clover HealthTech Co Ltd
Hemostemix Inc
Humanetics Corp
ILGEN Inc
Initiator Pharma AS
IntelGenx Corp
Jiangsu Hengrui Medicine Co Ltd
Klaria Pharma Holding AB
Lexaria Bioscience Corp
MannKind Corp
Mezzion Pharma Co Ltd
MicroCures Inc
Mitsubishi Tanabe Pharma Corp
MyX Therapeutics Inc
NAL Pharmaceuticals Ltd
Organicell Regenerative Medicine Inc
Orgenesis Inc
PeLeMed Co Ltd
Pharmicell Co Ltd
Reven Holdings Inc
S1 Biopharma Inc
Seelos Therapeutics, Inc.
Shandong Lukang Pharmaceutical Co Ltd
siRNAgen Therapeutics Corp
Targazyme Inc
Tavanta Therapeutics Inc
Techfields Pharma Co Ltd
Tritech Biopharmaceuticals Co Ltd
Venturis Therapeutics Inc
XuanZhu Biological Technology Co Ltd
Yangtze River Pharmaceutical Group

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Erectile Dysfunction – Overview

Erectile Dysfunction – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Erectile Dysfunction – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Erectile Dysfunction – Companies Involved in Therapeutics Development

AnyGen Co Ltd

Aprogen Inc

Aquestive Therapeutics Inc

Arovella Therapeutics Ltd

Astellas Pharma Inc

Autotelic Bio Inc

Benuvia Therapeutics Inc

Biozeus Pharmaceutical SA

Can-Fite BioPharma Ltd

Chengdu Dikang Pharmaceuticals Co Ltd

Cure Pharmaceutical Holding Corp

Dicot AB

Evincis Bio Inc

Exopharm Ltd

Fabre-Kramer Pharmaceuticals Inc

Farmalider SA

Guangzhou Four-Leaf Clover HealthTech Co Ltd

Hemostemix Inc

Humanetics Corp

ILGEN Inc

Initiator Pharma AS

IntelGenx Corp

Jiangsu Hengrui Medicine Co Ltd

Klaria Pharma Holding AB

Lexaria Bioscience Corp

MannKind Corp

Mezzion Pharma Co Ltd

MicroCures Inc

Mitsubishi Tanabe Pharma Corp

MyX Therapeutics Inc

NAL Pharmaceuticals Ltd

Organicell Regenerative Medicine Inc

Orgenesis Inc

PeLeMed Co Ltd

Pharmicell Co Ltd

Reven Holdings Inc

S1 Biopharma Inc

Seelos Therapeutics, Inc.

Shandong Lukang Pharmaceutical Co Ltd

siRNAgen Therapeutics Corp

Targazyme Inc

Tavanta Therapeutics Inc

Techfields Pharma Co Ltd

Tritech Biopharmaceuticals Co Ltd

Venturis Therapeutics Inc

XuanZhu Biological Technology Co Ltd

Yangtze River Pharmaceutical Group

Erectile Dysfunction – Drug Profiles

ACP-01 – Drug Profile

Product Description

Mechanism Of Action

AGM-175 – Drug Profile

Product Description

Mechanism Of Action

alprostadil – Drug Profile

Product Description

Mechanism Of Action

History of Events

AN-788 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Antisense RNAi Oligonucleotides for Atopy, Erectile Dysfunction, Heart Failure and Psoriasis – Drug Profile

Product Description

Mechanism Of Action

AP-185 – Drug Profile

Product Description

Mechanism Of Action

apomorphine – Drug Profile

Product Description

Mechanism Of Action

avanafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologics for Erectile Dysfunction – Drug Profile

Product Description

Mechanism Of Action

BZ-371 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellgram-ED – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cevaris – Drug Profile

Product Description

Mechanism Of Action

History of Events

CF-602 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CMS-203 – Drug Profile

Product Description

Mechanism Of Action

CVBT-141 – Drug Profile

Product Description

Mechanism Of Action

DDCI-01 – Drug Profile

Product Description

Mechanism Of Action

Drug for Erectile Dysfunction – Drug Profile

Product Description

Mechanism Of Action

EVI-200 – Drug Profile

Product Description

Mechanism Of Action

History of Events

fadanafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

FKK-01PD – Drug Profile

Product Description

Mechanism Of Action

genistein – Drug Profile

Product Description

Mechanism Of Action

History of Events

ILG-F – Drug Profile

Product Description

Mechanism Of Action

IPED-2015 – Drug Profile

Product Description

Mechanism Of Action

History of Events

libiguins – Drug Profile

Product Description

Mechanism Of Action

mirabegron ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

PLM-201 – Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction – Drug Profile

Product Description

Mechanism Of Action

RPCV-1005A – Drug Profile

Product Description

Mechanism Of Action

S1P-205 – Drug Profile

Product Description

Mechanism Of Action

siFi-2 – Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil citrate – Drug Profile

Product Description

Mechanism Of Action

sildenafil citrate – Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil ODF – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit PDE5 for Erectile Dysfunction – Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Erectile Dysfunction – Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Premature Ovarian Failure and Erectile Dysfunction – Drug Profile

Product Description

Mechanism Of Action

SUD-003 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SVF-CLI/ED – Drug Profile

Product Description

Mechanism Of Action

tadalafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

tadalafil – Drug Profile

Product Description

Mechanism Of Action

tadalafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

tadalafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

tadalafil – Drug Profile

Product Description

Mechanism Of Action

tadalafil IR – Drug Profile

Product Description

Mechanism Of Action

History of Events

TF-0092 – Drug Profile

Product Description

Mechanism Of Action

TPN-171 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TPN-729 – Drug Profile

Product Description

Mechanism Of Action

udenafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

vardenafil – Drug Profile

Product Description

Mechanism Of Action

History of Events

vardenafil hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Yonkenafil – Drug Profile

Product Description

Mechanism Of Action

Erectile Dysfunction – Dormant Projects

Erectile Dysfunction – Discontinued Products

Erectile Dysfunction – Product Development Milestones

Featured News & Press Releases

Mar 03, 2022: CURE Pharmaceutical and Milagro Pharmaceuticals collaborate for registration and approval to sell sildenafil oral thin film in Mexico

Feb 21, 2022: Dicot has identified several new patent opportunities

Dec 21, 2021: European Association of Urology has selected Dicot’s study result to be presented

Dec 06, 2021: Dicot’s study results will be presented at a leading scientific congress

Dec 02, 2021: Dicot’s potency drug candidate demonstrates efficiency and long duration even at a low dose

Nov 16, 2021: CURE Pharmaceutical receives patent approval for Its CUREfilm Blue Technology

Oct 20, 2021: Due to positive study results Dicot publishes a supplement prospectus

Sep 24, 2021: Initiator Pharma includes the first patient in Phase 2b study with IPED2015 in erectile dysfunction patients

Sep 14, 2021: Lukang Pharmaceutical CMS203 tablets obtained the “Notice of Drug Clinical Trial Approval”

Aug 24, 2021: Dicot: Proven long-term effect for Dicot’s drug candidate

Jun 28, 2021: Initiator Pharma receives CTA approval for Phase 2b study with IPED2015 in Erectile Dysfunction patients

Jun 02, 2021: Initiator Pharma – Phase 2a study with IP2018 update

Apr 21, 2021: CURE Pharmaceutical announces successful results from initial clinical trials for erectile dysfunction product CUREfilm Blue

Mar 24, 2021: Dicot begins its first studies on sick animals

Mar 18, 2021: Can-Fite: Topical administration of CF602 fully recovers erectile dysfunction in diabetic model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Erectile Dysfunction, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Erectile Dysfunction – Pipeline by AnyGen Co Ltd, 2022

Erectile Dysfunction – Pipeline by Aprogen Inc, 2022

Erectile Dysfunction – Pipeline by Aquestive Therapeutics Inc, 2022

Erectile Dysfunction – Pipeline by Arovella Therapeutics Ltd, 2022

Erectile Dysfunction – Pipeline by Astellas Pharma Inc, 2022

Erectile Dysfunction – Pipeline by Autotelic Bio Inc, 2022

Erectile Dysfunction – Pipeline by Benuvia Therapeutics Inc, 2022

Erectile Dysfunction – Pipeline by Biozeus Pharmaceutical SA, 2022

Erectile Dysfunction – Pipeline by Can-Fite BioPharma Ltd, 2022

Erectile Dysfunction – Pipeline by Chengdu Dikang Pharmaceuticals Co Ltd, 2022

Erectile Dysfunction – Pipeline by Cure Pharmaceutical Holding Corp, 2022

Erectile Dysfunction – Pipeline by Dicot AB, 2022

Erectile Dysfunction – Pipeline by Evincis Bio Inc, 2022

Erectile Dysfunction – Pipeline by Exopharm Ltd, 2022

Erectile Dysfunction – Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2022

Erectile Dysfunction – Pipeline by Farmalider SA, 2022

Erectile Dysfunction – Pipeline by Guangzhou Four-Leaf Clover HealthTech Co Ltd, 2022

Erectile Dysfunction – Pipeline by Hemostemix Inc, 2022

Erectile Dysfunction – Pipeline by Humanetics Corp, 2022

Erectile Dysfunction – Pipeline by ILGEN Inc, 2022

Erectile Dysfunction – Pipeline by Initiator Pharma AS, 2022

Erectile Dysfunction – Pipeline by IntelGenx Corp, 2022

Erectile Dysfunction – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Erectile Dysfunction – Pipeline by Klaria Pharma Holding AB, 2022

Erectile Dysfunction – Pipeline by Lexaria Bioscience Corp, 2022

Erectile Dysfunction – Pipeline by MannKind Corp, 2022

Erectile Dysfunction – Pipeline by Mezzion Pharma Co Ltd, 2022

Erectile Dysfunction – Pipeline by MicroCures Inc, 2022

Erectile Dysfunction – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022

Erectile Dysfunction – Pipeline by MyX Therapeutics Inc, 2022

Erectile Dysfunction – Pipeline by NAL Pharmaceuticals Ltd, 2022

Erectile Dysfunction – Pipeline by Organicell Regenerative Medicine Inc, 2022

Erectile Dysfunction – Pipeline by Orgenesis Inc, 2022

Erectile Dysfunction – Pipeline by PeLeMed Co Ltd, 2022

Erectile Dysfunction – Pipeline by Pharmicell Co Ltd, 2022

Erectile Dysfunction – Pipeline by Reven Holdings Inc, 2022

Erectile Dysfunction – Pipeline by S1 Biopharma Inc, 2022

Erectile Dysfunction – Pipeline by Seelos Therapeutics, Inc., 2022

Erectile Dysfunction – Pipeline by Shandong Lukang Pharmaceutical Co Ltd, 2022

Erectile Dysfunction – Pipeline by siRNAgen Therapeutics Corp, 2022

Erectile Dysfunction – Pipeline by Targazyme Inc, 2022

Erectile Dysfunction – Pipeline by Tavanta Therapeutics Inc, 2022

Erectile Dysfunction – Pipeline by Techfields Pharma Co Ltd, 2022

Erectile Dysfunction – Pipeline by Tritech Biopharmaceuticals Co Ltd, 2022

Erectile Dysfunction – Pipeline by Venturis Therapeutics Inc, 2022

Erectile Dysfunction – Pipeline by XuanZhu Biological Technology Co Ltd, 2022

Erectile Dysfunction – Pipeline by Yangtze River Pharmaceutical Group, 2022

Erectile Dysfunction – Dormant Projects, 2022

Erectile Dysfunction – Dormant Projects, 2022 (Contd..1)

Erectile Dysfunction – Dormant Projects, 2022 (Contd..2)

Erectile Dysfunction – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Erectile Dysfunction, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.